Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: Standardization is needed

Breast Cancer Research and Treatment

Volumn 113, Issue 1, 2009, Pages 123-128

  Mukai, Hirofumi ^a   Watanabe, Toru ^b   Ando, Masashi ^c   Shimizu, Chikako ^c   Katsumata, Noriyuki ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Hamamatsu Pharma Research Inc   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Aberdeen classification; Docetaxel; Doxorubicin; GEPARDO Trial; Japanese Breast Cancer Society; NSABP; Pathological complete response; Primary chemotherapy; University of Texas M.D. Anderson Cancer Center

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PARAMETER; PATHOLOGICAL COMPLETE RESPONSE; PERIPHERAL EDEMA; PHLEBITIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STANDARDIZATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TIME FACTORS;

EID: 58049208408     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-007-9889-9     Document Type: Article

References (23)

1. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
2. G Bonadonna P Valagussa R Zucali 1995 Primary chemotherapy in surgically resectable breast cancer CA Cancer J Clin 45 227 243
3. L Harris SM Swain 1996 The role of primary chemotherapy in early breast cancer Semin Oncol 23 31 42
4. IE Smith G Walsh A Jones 1995 High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer J Clin Oncol 13 424 429
5. ED Anderson AP Forrest RA Hawkins 1991 Primary systemic therapy for operable breast cancer Br J Cancer 63 561 566
6. M Kaufmann F Kubli 1983 Current state of chemosensitivity testing of tumors Dtsch Med Wochenschr 108 150 154
7. HM Kuerer LA Newman TL Smith 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469
8. M Kurosumi F Akiyama T Iwase 2001 Histopathological criteria for assessment of therapeutic response in breast cancer Breast Cancer 8 1 2
9. G von Minckwitz SD Costa G Raab 2001 Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study J Clin Oncol 19 3506 3515
10. HP Sinn H Schmid H Junkermann 1994 Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy Geburtshilfe Frauenheilkd 54 552 558
11. MC Green AU Buzdar T Smith 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992
12. G von Minckwitz SD Costa W Eiermann 1999 Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel J Clin Oncol 17 1999 2005
13. PM Ravdin HA Burris 3rd G Cook 1995 Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 2879 2885
14. V Valero FA Holmes RS Walters 1995 Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer J Clin Oncol 13 2886 2894
15. IC Smith SD Heys AW Hutcheon 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456 1466
16. E Kaplan P Meire 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481
17. G Bonadonna P Valagussa A Moliterni 1995 Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 901 906
18. Early Breast Cancer Trialist' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 942
19. JA van der Hage CJ van de Velde JP Julien 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237
20. A Makris TJ Powles SE Ashley 1998 A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1179 1184
21. SM Scholl A Fourquet B Asselain 1994 Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 Eur J Cancer 30A 645 652
22. G von Minckwitz G Raab A Caputo 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2676 2685
23. Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr:96-102